Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.6% | 40% | -78.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 87.9% | 83.1% | 96.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -494.8% | -429.7% | -983% | -174.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -498.1% | -420.8% | -863% | -70.1% |
| EPS Diluted | -0.046 | -0.054 | -0.098 | -0.038 |
| % Growth | 15.5% | 44.9% | -158.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |